Holen Sie sich die Stockscreener-App
4.38
22.69%
0.81
Vorhandelsmarkt:
4.42
0.04
+0.91%
Leonabio Inc Aktie (LONA) Neueste Nachrichten
LeonaBio Opens Warrant Exercise Window for New Capital - TipRanks
LeonaBio warrants exercisable could raise $146.2M if fully cash‑exercised - TradingView
LeonaBio Inc. (LONA) Slips 2.30% to $6.79, Drifting Toward Support at $6.45BPI Bear Correction - dars.gov.et
Mizuho Securities Maintains LeonaBio(LONA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com South Africa
LeonaBio to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
LONA Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 37.97% EPS SurpriseEstimate Dispersion - dars.gov.et
Perceptive Advisors LLC Expands LeonaBio Inc (LONA) Stake in Str - GuruFocus
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake - TradingView
Prefunded warrants drive Sermonix-led LeonaBio (LONA) share shakeup - Stock Titan
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
LeonaBio Reaches Key Phase 3 Enrollment Milestone - TipRanks
Perceptive's LeonaBio (NASDAQ: LONA) stake nears its ownership limit - Stock Titan
Anders Hove reports new passive stake in LeonaBio (LONA) - Stock Titan
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones - Pulse 2.0
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - vinanet.vn
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - vinanet.vn
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio’s lasofoxifene to be featured at breast cancer summit By Investing.com - Investing.com Nigeria
LeonaBio’s lasofoxifene to be featured at breast cancer summit - Investing.com
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer - The Manila Times
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), - GlobeNewswire
LONA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares RiseEarnings Stability Report - careplusvn.com
LONA Q1 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineEPS Growth Report - vinanet.vn
LONA: LeonaBio, Inc.12 Month EPS - Zacks Investment Research
LONA Q1 2026 Earnings: EPS Surprises Positively by 32.16% as Shares Retreat 3.76%Revenue Estimate Trend - dars.gov.et
LeonaBio Inc. (LONA) Slips 2.74% to $7.45 as Biotech Stock Nears Key SupportETF NAV Deviation - careplusvn.com
LeonaBio Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
1.48%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):